PMID- 38487467
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240316
IS  - 2673-6101 (Electronic)
IS  - 2673-6101 (Print)
IS  - 2673-6101 (Linking)
VI  - 5
DP  - 2024
TI  - House dust mite sublingual allergen immunotherapy tablet is safe and 
      well-tolerated in Dutch clinical practice.
PG  - 1355324
LID - 10.3389/falgy.2024.1355324 [doi]
LID - 1355324
AB  - BACKGROUND: Half (49%) of clinically diagnosed allergic rhinitis (AR) patients 
      are sensitized to house dust mite (HDM). If allergen avoidance and symptomatic 
      medication fail, allergen immunotherapy may be indicated. OBJECTIVE: We 
      investigated safety and tolerability of HDM-sublingual immunotherapy by HDM-SLIT 
      tablets in Dutch daily clinical practice. METHODS: Daily intake of 12 SQ-HDM 
      SLIT-tablet was investigated in a prospective, multicenter, observational study 
      (EUPAS43753). It comprised 4 consultations in 1 year. Data on safety, 
      tolerability, treatment satisfaction, symptomatic medication, compliance, and 
      clinical effectiveness (Control of Allergic Rhinitis and Asthma Test; CARAT) were 
      collected. Descriptive and longitudinal regression data analysis were performed. 
      RESULTS: Adult patients (n = 415), mean (SD) age 36.6 (12.2) years, 61.4% female 
      and 36% asthmatic were included. The preponderance (65.1%) experienced adverse 
      events (AEs). These, mostly mild (67%), AEs comprised: oral allergic reactions 
      (58.6%), respiratory (12.4%) and gastrointestinal symptoms (9.4%). Sixty (14.5%) 
      patients stopped due to AEs and 76 (18.3%) for non-AE reasons. CARAT scores 
      improved clinically significant by 6 points and symptomatic medication use 
      decreased from 96.1% to 77.4%. Most patients (74.5%) tolerated the treatment and 
      were compliant (>86.5%). The majority of patients (62.4%) and investigators 
      (69.4%) were satisfied with treatment. CONCLUSIONS: HDM SLIT-tablet is a safe and 
      well-tolerated AR treatment. AEs occur often but are mostly mild and decreasing 
      during the first year. CARAT scores improved and symptomatic medication use 
      decreased suggesting better control of AR with treatment. Compliance, 
      tolerability, and treatment satisfaction are good. However, patient follow-up and 
      compliance remain important points of attention when initiating treatment.
CI  - (c) 2024 Tempels-Pavlica, Aarts, Welsing, van der Meer, van der Zwan, Uss and 
      Knulst.
FAU - Tempels-Pavlica, Zana
AU  - Tempels-Pavlica Z
AD  - Department of Allergology, Diakonessenhuis, Utrecht, Netherlands.
FAU - Aarts, Mark C J
AU  - Aarts MCJ
AD  - Department of Otorhinolaryngology, Jeroen Bosch Hospital, 's-Hertogenbosch, 
      Netherlands.
FAU - Welsing, Paco M J
AU  - Welsing PMJ
AD  - Department of Rheumatology & Clinical Immunology, University Medical Centre 
      Utrecht, Utrecht, Netherlands.
FAU - van der Meer, Akke-Nynke
AU  - van der Meer AN
AD  - Department of Pulmonary Diseases, Medical Centre Leeuwarden, Leeuwarden, 
      Netherlands.
FAU - van der Zwan, Leonard P
AU  - van der Zwan LP
AD  - Medical Department, ALK-Abello BV, Almere, Netherlands.
FAU - Uss, Elena
AU  - Uss E
AD  - Medical Department, ALK-Abello BV, Almere, Netherlands.
FAU - Knulst, Andre C
AU  - Knulst AC
AD  - Department of Dermatology and Allergology, University Medical Centre Utrecht, 
      Utrecht University, Utrecht, Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20240229
PL  - Switzerland
TA  - Front Allergy
JT  - Frontiers in allergy
JID - 9918227355906676
PMC - PMC10937523
OTO - NOTNLM
OT  - Control of Allergic Rhinitis and Asthma Test (CARAT)
OT  - allergic rhinitis
OT  - general medicine
OT  - house dust mite (HDM)
OT  - non-interventional study
OT  - outpatient clinic
OT  - safety
OT  - sublingual immunotherapy tablet
COIS- Author (all authors) and research fees are paid by ALK-Abello BV. Two authors (5 
      and 6) work for ALK-Abello BV. The study was funded by ALK-Abello BV. The funder 
      had the following involvement in the study: study sponsor.
EDAT- 2024/03/15 06:44
MHDA- 2024/03/15 06:45
PMCR- 2024/02/29
CRDT- 2024/03/15 04:09
PHST- 2023/12/13 00:00 [received]
PHST- 2024/02/16 00:00 [accepted]
PHST- 2024/03/15 06:45 [medline]
PHST- 2024/03/15 06:44 [pubmed]
PHST- 2024/03/15 04:09 [entrez]
PHST- 2024/02/29 00:00 [pmc-release]
AID - 10.3389/falgy.2024.1355324 [doi]
PST - epublish
SO  - Front Allergy. 2024 Feb 29;5:1355324. doi: 10.3389/falgy.2024.1355324. 
      eCollection 2024.